- Home
- BYRN vs EQ Comparison
BYRN vs EQ Comparison
Compare BYRN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYRN | EQ |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.3M | 129.0M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BYRN | EQ |
|---|---|---|
| Price | $5.81 | $3.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $23.17 | $8.00 |
| AVG Volume (30 Days) | 343.9K | ★ 928.7K |
| Earning Date | 04-09-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $16,566,295.00 | ★ $41,095,000.00 |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $16.86 | N/A |
| P/E Ratio | $196.67 | ★ N/A |
| Revenue Growth | ★ 1692.08 | N/A |
| 52 Week Low | $4.84 | $0.29 |
| 52 Week High | $33.56 | $3.45 |
Technical Indicators
Market Signals| Indicator | BYRN | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 47.40 | 62.04 |
| Support Level | $5.71 | $1.54 |
| Resistance Level | $6.80 | $3.45 |
| Average True Range (ATR) | 0.36 | 0.35 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.79 | 67.21 |
Price Performance
Historical ComparisonAbout BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.